Kenneth A Jacobson Selected Research

Adenosine (Adenocard)

1/2022	A2A Adenosine Receptor Antagonists in Neurodegenerative Diseases.
1/2022	Machine Learning for Discovery of New ADORA Modulators.
1/2021	Optical control of adenosine A3 receptor function in psoriasis.
1/2021	Purinergic Signaling in Liver Pathophysiology.
1/2021	Adenosine A3 agonists reverse neuropathic pain via T cell-mediated production of IL-10.
1/2021	Adenosine Metabotropic Receptors in Chronic Pain Management.
1/2021	Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets.
1/2020	Chronic Morphine-Induced Changes in Signaling at the A3 Adenosine Receptor Contribute to Morphine-Induced Hyperalgesia, Tolerance, and Withdrawal.
1/2020	Treatment of chronic neuropathic pain: purine receptor modulation.
1/2020	Activation of neuronal adenosine A1 receptors causes hypothermia through central and peripheral mechanisms.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kenneth A Jacobson Research Topics

Disease

29	Neoplasms (Cancer) 10/2022 - 01/2005
24	Inflammation (Inflammations) 03/2022 - 01/2002
21	Ischemia 04/2022 - 03/2003
21	Neuralgia (Stump Neuralgia) 01/2022 - 01/2012
20	Pain (Aches) 04/2022 - 06/2003
20	Astrocytoma (Pilocytic Astrocytoma) 01/2021 - 01/2002
11	Hypoxia (Hypoxemia) 01/2022 - 06/2003
10	Chronic Pain 07/2021 - 05/2012
9	Asthma (Bronchial Asthma) 01/2022 - 11/2005
9	Infarction (Infarctions) 01/2020 - 06/2005
9	Heart Failure 01/2020 - 08/2005
8	Parkinson Disease (Parkinson's Disease) 04/2022 - 05/2011
8	Neurodegenerative Diseases (Neurodegenerative Disease) 04/2022 - 03/2009
7	Thrombosis (Thrombus) 01/2019 - 04/2005
6	Hypothermia 01/2022 - 02/2016
6	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 01/2009
5	Obesity 01/2022 - 04/2020
5	Dry Eye Syndromes (Dry Eye Syndrome) 01/2020 - 07/2010
5	Cystic Fibrosis (Mucoviscidosis) 12/2016 - 05/2004
5	Myocardial Infarction 05/2014 - 04/2006
5	Reperfusion Injury 09/2012 - 01/2006
4	Insulin Resistance 10/2021 - 01/2017
4	Glaucoma 03/2021 - 01/2009
4	Rheumatoid Arthritis 01/2019 - 01/2005
3	Peripheral Nervous System Diseases (PNS Diseases) 01/2022 - 12/2014
3	Type 2 Diabetes Mellitus (MODY) 01/2022 - 04/2013
3	Hyperalgesia 01/2022 - 02/2015
3	Hypersensitivity (Allergy) 01/2021 - 02/2015
3	Body Weight (Weight, Body) 01/2021 - 02/2007
3	Stroke (Strokes) 12/2020 - 05/2014
3	Cardiovascular Diseases (Cardiovascular Disease) 10/2016 - 05/2010
3	Leukemia 07/2013 - 03/2002
2	Alzheimer Disease (Alzheimer's Disease) 04/2022 - 03/2009
2	Pneumonia (Pneumonitis) 01/2022 - 05/2004
2	Neuroinflammatory Diseases 01/2022 - 01/2020
2	Cognitive Dysfunction 01/2022 - 01/2022
2	Atrial Fibrillation 03/2021 - 05/2011
2	Fibrosis (Cirrhosis) 01/2021 - 02/2014
2	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 01/2019
2	Metabolic Diseases (Metabolic Disease) 01/2021 - 12/2020
2	Non-alcoholic Fatty Liver Disease 01/2021 - 01/2020
2	Colitis 01/2020 - 12/2017
2	Abdominal Pain (Pain, Abdominal) 01/2020 - 12/2017

Drug/Important Bio-Agent (IBA)

44	Purinergic P1 Receptors (Adenosine Receptor)IBA 06/2022 - 07/2002
37	Adenosine (Adenocard)FDA LinkGeneric 01/2022 - 09/2003
15	NucleotidesIBA 01/2022 - 06/2003
15	Pharmaceutical PreparationsIBA 01/2022 - 05/2004
13	Adenosine Triphosphate (ATP)IBA 03/2022 - 02/2003
10	N(6)- (3- iodobenzyl)- 5'- N- methylcarboxamidoadenosineIBA 07/2021 - 03/2002
9	LigandsIBA 06/2022 - 10/2008
9	NucleosidesIBA 01/2022 - 09/2003
9	Purinergic Receptors (Receptors, Purine)IBA 01/2022 - 02/2007
9	Uridine Diphosphate (UDP)IBA 01/2021 - 06/2003
9	Type C PhospholipasesIBA 05/2014 - 01/2002
8	CalciumIBA 03/2021 - 02/2003
6	UridineIBA 01/2022 - 04/2005
6	MRS5698IBA 01/2021 - 12/2014
6	Adenosine Diphosphate (ADP)IBA 02/2015 - 12/2002
6	Uridine Triphosphate (UTP)IBA 05/2014 - 04/2005
5	Adenosine A3 ReceptorIBA 03/2022 - 01/2015
5	Adenosine Monophosphate (AMP)IBA 01/2022 - 06/2010
5	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 05/2010
5	Adenosine A1 ReceptorIBA 10/2021 - 08/2015
5	Adenosine KinaseIBA 04/2021 - 01/2015
5	Uridine Diphosphate Glucose (UDP Glucose)IBA 01/2021 - 12/2009
5	methylthio-ADPIBA 10/2007 - 07/2004
4	Analgesics (Analgesic Drugs)IBA 01/2022 - 01/2015
4	GTP-Binding Proteins (G-Protein)IBA 10/2019 - 05/2014
4	Purinergic P1 Receptor AgonistsIBA 01/2019 - 12/2014
4	purinoceptor P2Y6IBA 10/2017 - 06/2003
4	CalsequestrinIBA 01/2015 - 02/2007
3	Purinergic P1 Receptor AntagonistsIBA 04/2022 - 02/2014
3	AdiponectinIBA 01/2022 - 01/2017
3	Opioid Analgesics (Opioids)IBA 01/2022 - 01/2020
3	ProdrugsIBA 01/2022 - 05/2014
3	Proteins (Proteins, Gene)FDA Link 07/2021 - 07/2005
3	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 03/2021 - 11/2014
3	Interleukin-10 (Interleukin 10)IBA 01/2021 - 02/2015
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 05/2012
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2020 - 05/2012
3	Purinergic P2Y1 ReceptorsIBA 01/2020 - 07/2005
3	Prasugrel Hydrochloride FDA Link 01/2019 - 07/2012
3	TicagrelorIBA 01/2019 - 07/2012
3	Clopidogrel (Plavix)FDA Link 01/2019 - 07/2012
3	4- (2- chloro- 6- (3- chlorobenzylamino)- 9H- purin- 9- yl)- 2,3- dihydroxy- N- methylbicyclo(3.1.0)hexane- 1- carboxamideIBA 09/2010 - 01/2006
3	Phosphotransferases (Kinase)IBA 04/2009 - 06/2003
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2006 - 06/2003
2	Amyloid (Amyloid Fibrils)IBA 04/2022 - 01/2022
2	Peptides (Polypeptides)IBA 04/2022 - 01/2022
2	Caffeine (No Doz)FDA LinkGeneric 01/2022 - 11/2014
2	GlucocorticoidsIBA 01/2021 - 12/2010
2	Morphine (MS Contin)FDA LinkGeneric 01/2020 - 12/2017
2	MRS 2339IBA 01/2020 - 02/2007
2	bicyclo(3.1.0)hexaneIBA 01/2020 - 02/2013
2	Phosphates (Orthophosphate)IBA 01/2020 - 02/2013

Therapy/Procedure

16	Therapeutics 04/2022 - 01/2006
5	Drug Therapy (Chemotherapy) 01/2022 - 12/2014
3	Analgesia 01/2015 - 06/2003
3	Ligation 06/2013 - 10/2006
2	Immunotherapy 10/2022 - 01/2022